Vilon (Lysyl-Glutamic acid) is a short synthetic dipeptide subject to extensive investigation in epigenetic regulation and cellular repair models. Laboratory researchers evaluate Vilon for its potential to induce chromatin decondensation, activate silent genomic regions, and promote hepatocyte proliferation in preclinical hepatic injury models.
Vilon (Lysyl-Glutamic acid) is a short synthetic dipeptide subject to extensive investigation in epigenetic regulation and cellular repair models. Laboratory researchers evaluate Vilon for its potential to induce chromatin decondensation, activate silent genomic regions, and promote hepatocyte proliferation in preclinical hepatic injury models.
Vilon (Lys-Glu) is a synthetic short-chain dipeptide evaluated in preclinical models for its potential to modulate chromatin structure, stimulate hepatocyte proliferation, and accelerate hepatic tissue repair. Laboratory researchers buy Vilon for liver regeneration assays to examine epigenetic gene activation, protein synthesis, and cellular recovery following toxic or surgical tissue injury in controlled laboratory settings.
When procurement officers and principal investigators seek to buy research peptides for hepatic models, analytical purity and lot-to-lot consistency are essential. PX1 Research supplies high-purity, laboratory-grade Vilon manufactured in USA-based, GMP-compliant facilities. Every batch undergoes rigorous identity and purity validation via High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS) to support reproducible experimental outcomes across all in vitro and animal studies.
Vilon is a ultra-short peptide sequence composed of two essential amino acids: L-lysine and L-glutamic acid (Lys-Glu). Originally developed during investigations into thymic-derived bioregulatory peptides, Vilon belongs to a class of low-molecular-weight short peptides capable of direct interaction with the nuclear genome. Because of its minimal steric footprint and specific charge distribution, Vilon can cross cellular and nuclear membranes without requiring specialized transporter systems.
In nuclear transport assays, Lys-Glu demonstrates a selective affinity for histone proteins and specific DNA sequences. Researchers exploring Vilon epigenetic mechanisms observe that the dipeptide binds directly to nucleosomes, altering the ionic bonds between histone tails and DNA strands. This interaction induces localized chromatin decondensation, transforming dense heterochromatin into transcriptionally active euchromatin. This fundamental nuclear mechanism forms the baseline for evaluating how Vilon modulates gene expression patterns associated with structural protein synthesis and parenchymal cell renewal.
The liver exhibits a unique capacity for parenchymal regeneration, driven primarily by quiescent hepatocytes entering the cell cycle in response to tissue deficit or toxic insult. Preclinical literature indicates that Vilon plays a regulatory role in this regenerative cascade by upregulating key immediate-early genes and cyclin-dependent kinase pathways required for G1-to-S phase transition.
In vitro models utilizing isolated primary hepatocytes demonstrate that exposure to Vilon leads to a measurable increase in DNA synthesis and total cellular RNA accumulation. Preclinical studies suggest that Vilon modulates the transcription of key growth factor genes, including Hepatocyte Growth Factor (HGF) and Transforming Growth Factor-alpha (TGF-α). By enhancing endogenous signaling cascades without altering baseline cell line stability, researchers utilize Vilon dipeptide to investigate the temporal dynamics of liver repair, ribosomal biogenesis, and functional parenchymal restoration following standardized chemical or mechanical challenge.
Animal model experiments, particularly rodent studies involving partial hepatectomy or carbon tetrachloride (CCl4)-induced hepatic damage, provide important empirical data regarding Vilon's biological activity. In partial hepatectomy models, administration of Vilon accelerated the restoration of functional liver mass compared to saline controls, as measured by wet liver weight recovery and mitotic index tracking.
Furthermore, in vivo toxicological models demonstrate that Vilon administration correlates with reduced serum markers of acute hepatocellular injury, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Histological evaluations of liver tissue sections in these studies revealed attenuated necrosis, accelerated ballooning degeneration resolution, and enhanced expression of Ki-67 nuclear antigen—a definitive marker of active cellular proliferation. Investigators focused on hepatocyte proliferation peptides study these structural preservation metrics to clarify how short dipeptides modulate cellular resilience against oxidative stress and xenobiotic toxicity.
To contextualize Vilon within the broader landscape of bioregulatory and tissue-protective research compounds, researchers frequently compare its activity profile against other short-chain peptides. While Vilon (Lys-Glu) selectively targeting chromatin remodeling and thymic-hepatic signaling axis, other compounds operate through distinct biological pathways.
For example, Epitalon (Ala-Glu-Asp-Gly) primary mechanism involves telomerase activation and pineal regulation, whereas Vilon focuses more directly on general protein synthesis upregulation and immediate structural tissue repair. Similarly, KPV (Lys-Pro-Val) exhibits potent anti-inflammatory properties primarily via NF-κB pathway inhibition, making it complementary to Vilon's proliferative actions in tissue injury models. Meanwhile, BPC-157 acts through angiogenic growth factor modulation (such as VEGF) and nitric oxide signaling pathways. Understanding these biochemical distinctions allows laboratory researchers to design synergistic, multi-compound assays within our broader research peptide catalog.
Proper handling and storage protocols are critical to preserving the structural integrity and biological activity of Vilon dipeptide in experimental settings. Vilon is supplied as a lyophilized, highly purified white powder that requires precise reconstitution prior to use in cell culture or animal model assays.
To reconstitute Vilon for laboratory research use:
1. Reagent Preparation: Equilibrate the glass vial to room temperature prior to reconstitution to prevent moisture condensation inside the container.
2. Solvent Selection: Use sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory reagents, or sterile Phosphate-Buffered Saline (PBS, pH 7.4) for direct cell culture applications.
3. Solubilization Technique: Gently introduce the desired solvent volume down the inner wall of the vial. Swirl gently until the lyophilized cake fully dissolves. Avoid vortexing or vigorous agitation to prevent mechanical shear stress.
4. Storage and Stability: Store lyophilized Vilon at -20°C or -80°C for long-term stability. Aliquot reconstituted solutions into single-use polypropylene tubes to avoid freeze-thaw cycles and store at -80°C for up to 90 days, or at 4°C for up to 7 days.
When designing in vitro or in vivo experiments centered on hepatic cellular dynamics, researchers employ a variety of quantitative assays to track Vilon's biological activity:
• Cell Viability & Proliferation Assays: MTT, WST-1, or CCK-8 colorimetric assays to quantify hepatocyte metabolic activity and proliferation rates post-exposure.
• Gene Expression Profiling: Quantitative Real-Time PCR (qPCR) targeting albumin, HGF, cyclin D1, and anti-apoptotic markers (Bcl-2) following Vilon treatment.
• Chromatin Accessibility Assays: ATAC-seq or Micrococcal Nuclease (MNase) digestion assays to evaluate Vilon-induced changes in chromatin openness.
• Protein Synthesis Quantification: Western blotting and S-35 methionine incorporation assays to measure overall ribosomal translation rates in treated hepatocyte cultures.
Obtaining reproducible data in peptide research demands absolute chemical purity and batch integrity. Impurities, truncated sequences, or residual organic solvents can confound experimental outcomes and introduce unacceptable variance in cellular assays. PX1 Research enforces rigorous quality assurance protocols to guarantee that every lot of Vilon meets stringent analytical benchmarks.
Every batch of Vilon manufactured for PX1 Research is produced in US-based, GMP-compliant facilities and tested by an independent, ISO 17025-accredited laboratory. We verify chemical identity and purity through Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS), ensuring minimum purity levels exceeding 98.0%. Furthermore, all lots undergo Chromogenic LAL Endotoxin Testing to confirm bacterial endotoxin limits strictly below 0.01 EU/mg, protecting delicate cell culture models from endotoxin-induced inflammatory noise.
Principal investigators and institutional buyers interested in securing bulk quantities for long-term study designs can establish automated deliveries through our wholesale lab account portal, ensuring seamless access to fully traceable, lot-validated research compounds.
What is the primary mechanism of Vilon in liver regeneration research?
Vilon (Lys-Glu) acts primarily through nuclear chromatin decondensation and direct DNA interaction. Preclinical research demonstrates that Vilon binds to nucleosomes, inducing structural changes in heterochromatin that facilitate gene transcription, upregulate protein synthesis, and activate cyclin pathways necessary for hepatocyte proliferation.
Is Vilon intended for human therapeutic use or clinical treatment?
No. Vilon is supplied strictly as a research-grade compound for in vitro laboratory research and preclinical animal studies. It is not approved for human consumption, medical diagnosis, therapeutic treatment, or clinical administration.
What purity levels does PX1 Research guarantee for Vilon?
PX1 Research guarantees a minimum purity of 98.0% for Vilon dipeptide, as verified by lot-specific Reverse-Phase HPLC and Mass Spectrometry analysis performed by independent ISO 17025-accredited laboratories.
How should Vilon be stored upon receipt in the laboratory?
Lyophilized Vilon should be stored at -20°C or -80°C in a dry location away from light. Once reconstituted in sterile solvent, liquid aliquots should be frozen at -80°C to maintain stability and avoid repeated freeze-thaw cycles.
What solvents are recommended for reconstituting Vilon for in vitro assays?
For cell culture and in vitro bioassays, Vilon should be reconstituted in sterile, endo-free Phosphate-Buffered Saline (PBS, pH 7.4) or sterile water for injection. For multi-dispense laboratory stock solutions, 0.9% Bacteriostatic Water may be utilized.
What are the endotoxin limits for PX1 Research Vilon batches?
All Vilon lots supplied by PX1 Research undergo LAL endotoxin testing and are verified to contain less than 0.01 EU/mg of bacterial endotoxins, making them safe for sensitive cell culture and primary cell assays.
How does Vilon compare to Thymogen in research settings?
Vilon (Lys-Glu) and Thymogen (Glu-Trp) are both short bioregulatory dipeptides. However, Vilon is predominantly studied for its direct chromatin decondensation and structural tissue regeneration effects, whereas Thymogen (Glu-Trp) is primarily investigated for T-cell differentiation and immune system modulation.
Where does PX1 Research ship Vilon orders from?
All PX1 Research compounds are manufactured in the USA and shipped directly from our primary distribution centers located in California and Arizona, offering same-day dispatch for orders placed before cutoff times Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.